Spots Global Cancer Trial Database for respiratory tract disease

Every month we try and update this database with for respiratory tract disease cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)	NCT04222972	RET-fusion Non ... Lung Neoplasm Carcinoma, Non-... Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Disea... Head and Neck N... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Germ... Neoplasms, Nerv...	Pralsetinib Carboplatin Cisplatin Pemetrexed Pembrolizumab Gemcitabine Paclitaxel Nab-Paclitaxel	18 Years -	Hoffmann-La Roche
A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC	NCT03134872	Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Thoracic Neopla... Lung Diseases Respiratory Tra... Neoplasms by Si... Neoplasm, Bronc... Carcinoma, Bron...	SHR-1210 Carboplatin Pemetrexed	18 Years - 70 Years	Jiangsu HengRui Medicine Co., Ltd.
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements	NCT03093116	Locally Advance... Metastatic Soli...	Oral repotrecti...	12 Years -	Turning Point Therapeutics, Inc.
A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC	NCT03085069	Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Lung Disease Respiratory Tra... Neoplasm, Bronc... Carcinoma, Bron...	SHR-1210	18 Years - 80 Years	Jiangsu HengRui Medicine Co., Ltd.
A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC	NCT03134872	Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Thoracic Neopla... Lung Diseases Respiratory Tra... Neoplasms by Si... Neoplasm, Bronc... Carcinoma, Bron...	SHR-1210 Carboplatin Pemetrexed	18 Years - 70 Years	Jiangsu HengRui Medicine Co., Ltd.
A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC	NCT03085069	Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Lung Disease Respiratory Tra... Neoplasm, Bronc... Carcinoma, Bron...	SHR-1210	18 Years - 80 Years	Jiangsu HengRui Medicine Co., Ltd.
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC	NCT04862780	Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Nerv... EGFR T790M EGFR C797S EGFR L858R EGFR Gene Mutat... EGF-R Positive ... EGFR Exon 19 De... EGFR Mutation R... EGFR Activating... Protein Kinase ... Antineoplastic ... Thoracic Neopla...	BLU-945 osimertinib	18 Years -	Blueprint Medicines Corporation
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements	NCT03093116	Locally Advance... Metastatic Soli...	Oral repotrecti...	12 Years -	Turning Point Therapeutics, Inc.
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors	NCT03037385	RET-altered Non... Medullary Thyro... RET-altered Pap... RET-altered Col... RET-altered Sol... Lung Neoplasm Carcinoma, Non-... Thyroid Disease... Thyroid Neoplas... Thyroid Cancer,... Carcinoma, Neur... Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Endocrine Syste... Endocrine Gland... Head and Neck N... Adenocarcinoma,... Adenocarcinoma Carcinoma Neoplasms, Glan... Neoplasms by Hi... Neuroendocrine ... Neuroectodermal... Neoplasms, Germ... Neoplasms, Nerv... Colonic Neoplas... Colorectal Neop... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise...	pralsetinib (BL...	18 Years -	Hoffmann-La Roche
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations	NCT05241873	Lung Neoplasm M... Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... EGFR Exon 20 Mu... EGFR Exon 20 In... EGFR Activating... Antineoplastic ... Metastatic Lung... Brain Metastase... EGFR-mutated NS... EGFR Atypical M...	BLU-451 Carboplatin Pemetrexed	18 Years -	Blueprint Medicines Corporation
A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC	NCT03085069	Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Lung Disease Respiratory Tra... Neoplasm, Bronc... Carcinoma, Bron...	SHR-1210	18 Years - 80 Years	Jiangsu HengRui Medicine Co., Ltd.
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC	NCT04862780	Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Nerv... EGFR T790M EGFR C797S EGFR L858R EGFR Gene Mutat... EGF-R Positive ... EGFR Exon 19 De... EGFR Mutation R... EGFR Activating... Protein Kinase ... Antineoplastic ... Thoracic Neopla...	BLU-945 osimertinib	18 Years -	Blueprint Medicines Corporation

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: